Milestone Pharmaceuticals (NASDAQ:MIST), Inc. is a clinical‐stage biopharmaceutical company dedicated to developing novel therapies for gastrointestinal (GI) motility and functional disorders. Headquartered in Connecticut with operations extending across the United States and Europe, Milestone focuses on areas of significant unmet medical need such as diabetic gastroparesis, postoperative ileus and chronic idiopathic constipation. Through strategic collaborations and in‐license agreements, the company leverages specialized peptide technologies to address core pathophysiological mechanisms in GI disorders.
The company’s lead product candidate, relamorelin, is a potent ghrelin receptor agonist designed to accelerate gastric emptying and alleviate upper GI symptoms in patients with diabetic gastroparesis. In addition to relamorelin, Milestone is advancing a pipeline of next‐generation peptides targeting a broad spectrum of GI indications, including postoperative ileus and irritable bowel syndrome with constipation. These candidates are supported by robust preclinical and clinical data underscoring their potential to improve patient outcomes and quality of life.
Founded in 2019, Milestone Pharmaceuticals went public on the NASDAQ under the ticker “MIST” and has since built a focused portfolio through both internal discovery programs and partnerships with academic institutions. The company’s research and development efforts are complemented by a network of clinical collaborators and key opinion leaders in gastroenterology, enabling efficient trial execution and targeted patient recruitment. Milestone remains committed to advancing its pipeline through pivotal studies and regulatory interactions with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency.
Milestone is led by an executive team with extensive experience in pharmaceutical development, regulatory strategy and commercialization. The management group is supported by a board of directors composed of seasoned professionals in biotechnology, gastroenterology research and healthcare finance. Together, they guide Milestone’s mission to bring innovative, mechanism‐based therapies to patients suffering from debilitating GI disorders.
